+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Active Pharmaceutical Ingredients Market Outlook 2020-2030

  • ID: 5559888
  • Report
  • January 2022
  • Region: Global
  • 170 Pages
  • Research Nester Pvt. Ltd

FEATURED COMPANIES

  • API Corporation
  • Aurobindo Pharma
  • GlaxoSmithKline plc
  • KATSURA CHEMICAL CO. Ltd.
  • Novartis AG
  • Pfizer Inc.

Global Active Pharmaceutical Ingredients (API) Market Analysis 2020-2030


The global active pharmaceutical ingredients (API) market is anticipated to grow with a CAGR of 6.08% over the forecast period, i.e., 2021 - 2030. Factors such as the increasing number of generic drug approvals, followed by the growing demand for generic and biosimilar drugs, and the rising healthcare expenditure are anticipated to drive the growth of the market in the coming years. Moreover, factors such as the rising prevalence of chronic diseases worldwide, which is driving the need amongst the pharmaceutical drug manufacturers to develop advanced medicines to treat these diseases, is also expected to drive the demand for active pharmaceutical ingredients (APIs) in the coming years, and in turn, contribute to the growth of the market. The market is estimated to garner a revenue of near to USD 330 Billion by the end of 2030, up from a revenue of around USD 185 Billion in the year 2020.

The global active pharmaceutical ingredients (API) market is segmented by numerous segments, which include segmentation by type, synthesis type, therapeutic application, business mode, and by region. Based on therapeutic application, the market is segmented into communicable disease, oncology, diabetes, cardiovascular disease, musculoskeletal disorders, respiratory disorders, and other therapeutic applications. The cardiovascular disease segment is anticipated to garner the largest revenue of near to USD 70 Billion by the end of 2030, amongst all the other segments. Moreover, the segment generated a revenue of about USD 40 Billion in the year 2020.

On the basis of regional analysis, the global active pharmaceutical ingredients (API) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to garner the largest revenue of more than USD 125 Billion by the end of 2030 amongst the markets in all the other regions. Moreover, in the year 2020, the market in the region registered a revenue of around USD 70 Billion.

Some of the prominent industry leaders in the global active pharmaceutical ingredients (API) market that are included in our report are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi-aventis Groupe, Boehringer Ingelheim International GmbH, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., API Corporation, Bristol-Myers Squibb Company, KATSURA CHEMICAL CO., LTD., and others.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • API Corporation
  • Aurobindo Pharma
  • GlaxoSmithKline plc
  • KATSURA CHEMICAL CO. Ltd.
  • Novartis AG
  • Pfizer Inc.

1. Market Definition
1.1. Definition
1.2. Market Segmentation
2. Assumptions and Acronyms
3. Research Methodology
3.1. Research Process
3.2. Primary Research
3.3. Secondary Research
4. Executive Summary - Global Active Pharmaceutical Ingredients (API) Market
5. Market Dynamics
5.1. Market Drivers
5.2. Market Trends
6. Key Market Opportunities7. Major Roadblocks for the Market Growth8. Regulatory and Standards Landscape9. Industry Risk Analysis10. Pricing Analysis of Active Pharmaceutical Ingredients (API) Market11. Industry Value Chain Analysis
12. Trade Outlook
12.1. Import
12.2. Export
13. Impact of COVID-19 on the Active Pharmaceutical Ingredients (API) Market14. Product Feature Analysis15. Competitive Positioning
16. Competitive Structure
16.1. Market Share Analysis, 2020
16.2. Competitive Benchmarking
16.3. Company Profiles
16.3.1. Pfizer Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Novartis AG
16.3.4. Sanofi-aventis Groupe
16.3.5. Boehringer Ingelheim International GmbH
16.3.6. Aurobindo Pharma
16.3.7. Dr. Reddy’s Laboratories Ltd.
16.3.8. API Corporation
16.3.9. Bristol-Myers Squibb Company
16.3.10. KATSURA CHEMICAL CO., LTD.
17. Global Active Pharmaceutical Ingredients (API) Market Outlook
17.1. Market by Value (USD Billion)
17.2. Market Segmentation
17.2.1. By Type
17.2.1.1. Generic, 2020-2030F (USD Billion)
17.2.1.2. Innovative, 2020-2030F (USD Billion)
17.2.2. By Synthesis Type
17.2.2.1. Synthetic, 2020-2030F (USD Billion)
17.2.2.2. Biotech, 2020-2030F (USD Billion)
17.2.3. By Therapeutic Application
17.2.3.1. Communicable Diseases, 2020-2030F (USD Billion)
17.2.3.2. Oncology, 2020-2030F (USD Billion)
17.2.3.3. Diabetes, 2020-2030F (USD Billion)
17.2.3.4. Cardiovascular Disease, 2020-2030F (USD Billion)
17.2.3.5. Musculoskeletal Disorders, 2020-2030F (USD Billion)
17.2.3.6. Respiratory Diseases, 2020-2030F (USD Billion)
17.2.3.7. Other Therapeutic Applications, 2020-2030F (USD Billion)
17.2.4. By Business Mode
17.2.4.1. Captive, 2020-2030F (USD Billion)
17.2.4.2. Merchant, 2020-2030F (USD Billion)
17.2.5. By Region
17.2.5.1. North America, 2020-2030F (USD Billion)
17.2.5.2. Europe, 2020-2030F (USD Billion)
17.2.5.3. Asia Pacific, 2020-2030F (USD Billion)
17.2.5.4. Latin America, 2020-2030F (USD Billion)
17.2.5.5. Middle East & Africa, 2020-2030F (USD Billion)
18. North America Active Pharmaceutical Ingredients (API) Market Outlook
18.1. Market by Value (USD Billion)
18.2. Market Segmentation
18.2.1. By Type
18.2.1.1. Generic, 2020-2030F (USD Billion)
18.2.1.2. Innovative, 2020-2030F (USD Billion)
18.2.2. By Synthesis Type
18.2.2.1. Synthetic, 2020-2030F (USD Billion)
18.2.2.2. Biotech, 2020-2030F (USD Billion)
18.2.3. By Therapeutic Application
18.2.3.1. Communicable Diseases, 2020-2030F (USD Billion)
18.2.3.2. Oncology, 2020-2030F (USD Billion)
18.2.3.3. Diabetes, 2020-2030F (USD Billion)
18.2.3.4. Cardiovascular Disease, 2020-2030F (USD Billion)
18.2.3.5. Musculoskeletal Disorders, 2020-2030F (USD Billion)
18.2.3.6. Respiratory Diseases, 2020-2030F (USD Billion)
18.2.3.7. Other Therapeutic Applications, 2020-2030F (USD Billion)
18.2.4. By Business Mode
18.2.4.1. Captive, 2020-2030F (USD Billion)
18.2.4.2. Merchant, 2020-2030F (USD Billion)
18.2.5. By Country
18.2.5.1. United States, 2020-2030F (USD Billion)
18.2.5.2. Canada, 2020-2030F (USD Billion)
19. Europe Active Pharmaceutical Ingredients (API) Market Outlook
19.1. Market by Value (USD Billion)
19.2. Market Segmentation
19.2.1. By Type
19.2.2. By Synthesis Type
19.2.3. By Therapeutic Application
19.2.4. By Business Mode
19.2.5. By Country
19.2.5.1. United Kingdom, 2020-2030F (USD Billion)
19.2.5.2. Germany, 2020-2030F (USD Billion)
19.2.5.3. Italy, 2020-2030F (USD Billion)
19.2.5.4. France, 2020-2030F (USD Billion)
19.2.5.5. Spain, 2020-2030F (USD Billion)
19.2.5.6. Russia, 2020-2030F (USD Billion)
19.2.5.7. Netherlands, 2020-2030F (USD Billion)
19.2.5.8. Rest of Europe, 2020-2030F (USD Billion)
20. Asia Pacific Active Pharmaceutical Ingredients (API) Market Outlook
20.1. Market by Value (USD Billion)
20.2. Market Segmentation
20.2.1. By Type
20.2.2. By Synthesis Type
20.2.3. By Therapeutic Application
20.2.4. By Business Mode
20.2.5. By Country
20.2.5.1. Japan, 2020-2030F (USD Billion)
20.2.5.2. Australia, 2020-2030F (USD Billion)
20.2.5.3. Singapore, 2020-2030F (USD Billion)
20.2.5.4. South Korea, 2020-2030F (USD Billion)
20.2.5.5. India, 2020-2030F (USD Billion)
20.2.5.6. China, 2020-2030F (USD Billion)
20.2.5.7. Rest of Asia Pacific, 2020-2030F (USD Billion)
21. Latin America Active Pharmaceutical Ingredients (API) Market Outlook
21.1. Market by Value (USD Billion)
21.2. Market Segmentation
21.2.1. By Type
21.2.2. By Synthesis Type
21.2.3. By Therapeutic Application
21.2.4. By Business Mode
21.2.5. By Country
21.2.5.1. Brazil, 2020-2030F (USD Billion)
21.2.5.2. Argentina, 2020-2030F (USD Billion)
21.2.5.3. Mexico, 2020-2030F (USD Billion)
21.2.5.4. Rest of Latin America, 2020-2030F (USD Billion)
22. Middle East & Africa Active Pharmaceutical Ingredients (API) Market Outlook
22.1. Market by Value (USD Billion)
22.2. Market Segmentation
22.2.1. By Type
22.2.2. By Synthesis Type
22.2.3. By Therapeutic Application
22.2.4. By Business Mode
22.2.5. By Country
22.2.5.1. GCC, 2020-2030F (USD Billion)
22.2.5.2. Israel, 2020-2030F (USD Billion)
22.2.5.3. South Africa, 2020-2030F (USD Billion)
22.2.5.4. Rest of Middle East & Africa, 2020-2030F (USD Billion)
Note: Product cover images may vary from those shown
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Sanofi-aventis Groupe
  • Boehringer Ingelheim International GmbH
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.
  • API Corporation
  • Bristol-Myers Squibb Company
  • KATSURA CHEMICAL CO. Ltd.
Note: Product cover images may vary from those shown